Reveals metabolic reprogramming as a resistance mechanism in BRAF-Mutated multiple myeloma; OxPhos is an energy source for drug-persistent myeloma cells and negatively correlated with MAPK activation. The gene discussed is BRAF; the disease is plasma cell myeloma.